Carnitine palmitoyltransferase II deficiency

Carnitine palmitoyltransferase II (CPT II) deficiency is an inherited disorder of long-chain fatty acid mitochondrial oxidation caused by biallelic pathogenic variants in the CPT2 gene. It presents with an autosomal recessive inheritance pattern. Reduced CPT II activity impairs the proper utilization of fats as an energy source, particularly during fasting, prolonged exercise, infections, or other metabolic stress situations.

The CPT2 gene encodes mitochondrial carnitine O-palmitoyltransferase 2, an enzyme associated with the inner mitochondrial membrane and oriented towards the matrix. It is part of the carnitine shuttle, responsible for introducing long-chain fatty acids into the mitochondria. Following the formation and transport of acylcarnitines, CPT II regenerates long-chain acyl-CoAs, which can be incorporated into beta-oxidation to produce energy.

Pathogenic variants in CPT2 reduce the amount, stability, or catalytic activity of the enzyme. This limits energy production from fats and favors the accumulation of long-chain acylcarnitines, with a particular impact on skeletal muscle, liver, and heart. Three main presentations are described: a lethal neonatal form, a severe infantile hepatocardiomuscular form, and a myopathic form, which is the most frequent and generally the least severe. The exact population prevalence is not well established and the myopathic form may be underdiagnosed. A higher frequency has been reported in people of Ashkenazi Jewish ancestry and differences in predominant variants between populations.

Symptoms

The neonatal form begins during the first hours or days of life and can produce hypoketotic hypoglycemia, hyperammonemia, liver failure, cardiomyopathy, arrhythmias, respiratory distress, seizures, and coma. Cystic renal dysplasia and brain malformations may coexist, and the course is usually rapidly fatal. The infantile form usually appears during the first two years, with decompensations triggered by fasting or infection that cause hypoglycemia, hepatomegaly or liver failure, cardiomyopathy, arrhythmias, encephalopathy, and muscle weakness. The myopathic form can begin from infancy to adulthood and is characterized by episodes of muscle pain, cramps, weakness, rhabdomyolysis, and myoglobinuria. Attacks are usually precipitated by prolonged exercise, fasting, fever, infections, cold, stress, lack of sleep, or anesthesia. Many individuals remain asymptomatic between episodes, although intense rhabdomyolysis can cause acute kidney injury and require dialysis.

Disease management

Currently, there is no curative treatment. Management must be individualized by a team specializing in metabolic diseases and includes avoiding prolonged fasting, eating regular meals, maintaining sufficient energy intake, and having a written protocol for intercurrent illnesses, surgical procedures, and other catabolic situations. Depending on the clinical presentation, a diet rich in carbohydrates and restricted in long-chain fatty acids, with controlled intake of essential fatty acids, may be recommended. Triheptanoin can be used as an alternative energy source in certain patients; when it is not available, medium-chain triglycerides may be used under supervision. L-carnitine supplementation is controversial in long-chain fatty acid oxidation defects and should only be considered in selected cases with clearly low concentrations.

During decompensation, catabolism should be stopped early by providing glucose, even if initial glycemia is normal. In rhabdomyolysis episodes, intravenous hydration, monitoring of creatine kinase, electrolytes, renal function, and urinary myoglobin are required, along with treatment for kidney injury if it appears. Severe forms also require hepatic, cardiological, neurological, and respiratory monitoring. In the myopathic form, it is recommended to adapt physical activity, avoid prolonged exercise while fasting, and recognize muscle pain or dark urine early. There is currently no approved gene therapy for CPT II deficiency.

Genes analyzed

CPT2 U
U Ultra Whole Genome Sequencing 30x

Bibliography

LoPiccolo MK, Vockley J. Carnitine Palmitoyltransferase II Deficiency. GeneReviews®. Updated: April 9, 2026.

Orphanet. Carnitine palmitoyltransferase II deficiency. ORPHA:157.

Joshi PR, Deschauer M, Zierz S. Carnitine palmitoyltransferase II (CPT II) deficiency: genotype-phenotype analysis of 50 patients. J Neurol Sci. 2014;338(1-2):107-111.

Knottnerus SJG, Bleeker JC, Wüst RCI, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19(1):93-106.

Merritt JL 2nd, MacLeod E, Jurecka A, Hainline B. Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord. 2020;21(4):479-493.

Joshi PR, Zierz S. Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach. Molecules. 2020;25(8):1784.

What do your genes say about you? Start your journey today.

Get a special 5% discount on your first kit.

Haven't you taken our DNA test yet?

Get your genetic test and discover what your DNA says about you.

pack
Starter DNA test
The best option to get started

Ancestry service, Traits and Wellness

Buy
pack
DNA test Advanced DNA test
Know your DNA in depth

Health, Ancestry service, Traits and Wellness

Buy
pack
Genetic analysisUltra
Whole Genome Sequencing 30x

Health, Ancestrality, Traits and Wellness

includes three months of tellmeGen+

Buy

Important information and limitations

Europe
Austria
Belgium
Czech Republic
Denmark
Finland
Germany
Hungary
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Romania
Spain
Sweden
Switzerland
United Kingdom
Asia
Kazakhstan
Saudi Arabia
UAE
America
Brazil
Canada
Chile
Colombia
Mexico
Panama
Peru
United States
Oceania
Australia
The Best Prices of the Year! Only until November 27 Use our coupon BLACK15
Buy